Your session is about to expire
← Back to Search
HR20013 for injection+dexamethasone for Prevention of Nausea and Vomiting
Phase 1
Waitlist Available
Research Sponsored by Fujian Shengdi Pharmaceutical Co., Ltd.
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 0 to 504 hours
Awards & highlights
Summary
To evaluate the safety and pharmacokinetics of single-dose HR20013 for injection combined with dexamethasone in patients with malignant solid tumors receiving cisplatin-based chemotherapy.
Eligible Conditions
- Prevention of Nausea and Vomiting
Timeline
Screening ~ 3 weeks3 visits
Treatment ~ Varies
Follow Up ~ 0 to 504 hours
Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~0 to 504 hours
Treatment Details
Study Objectives
Study objectives can provide a clearer picture of what you can expect from a treatment.Secondary study objectives
Therapeutic procedure
Trial Design
1Treatment groups
Experimental Treatment
Group I: HR20013 for injection+dexamethasoneExperimental Treatment1 Intervention
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
HR20013 for injection;dexamethason
2022
Completed Phase 1
~30
Find a Location
Who is running the clinical trial?
Fujian Shengdi Pharmaceutical Co., Ltd.Lead Sponsor
25 Previous Clinical Trials
4,315 Total Patients Enrolled
Share this study with friends
Copy Link
Messenger